In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mid-Sized Purdue Fills Out

Executive Summary

Recent deals by mid-sized, privately owned Purdue fit a strategy carefully crafted to reduce the firm's dependence on a single big-selling drug..

You may also be interested in...



Purdue's OxyContin: A Blessing and a Curse

Purdue Pharma's best-selling opioid painkiller, OxyContin, is starting to look more like a curse than a blessing to the company as incidents of its abuse rise. The drug is being sold on the street like a narcotic, and publicity about pharmacies being robbed and overdose deaths caused by OxyContin could hurt sales. Purdue's not the first pharma company to stand accused of doing bad while trying to do good. But the company is frustrated, even as it takes precautions to stem abusive use of its product.

‘Buy American’ Executive Order Receives Backlash

To build a “reliable long-term domestic production” of medicines and related supplies and to “minimize potential shortages,” US President Donald Trump has signed a ‘Buy American’ executive order. However, the move has left industry wondering if it is a sustainable solution.

Bayer Back In M&A Mode To Boost Pipeline

The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel